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Abstract
Maternal plasma histamine levels in normal pregnancy are generally similar to those in non-pregnant
women during the ﬁrst trimester, and usually decline gradually during the 2nd and 3rd trimesters (Brew
and Sullivan, 2006). In some complications of pregnancy such as hyperemesis gravidarum (HG),
spontaneous abortion (SA), pre-term labour (PL) and Pre-eclampsia (PE) histamine levels increase as
pregnancy proceeds (Southren et al., 1966; Achari, Achari and Rao, 1971; Beaven et al., 1975), and
the elevated levels of histamine may directly cause some of the features of these disorders (Brew
and Sullivan, 2006).
 
Placenta is a major source of histamine, but it also releases active diamine amine oxidase (DAO; EC
1.4.3.22) into the maternal circulation, which metabolises histamine (Kapeller-Adler, 1944; Gunther
and Glick, 1967; Semeniuchenko, 1975; Granerus, Gillbrand and Wetterqvist, 1977; Purcell and
Hanahoe, 1991; Brew, Lakasing and Sullivan, 2007).  This breaks down the histamine released from
the placenta in normal pregnancy, leading to the limited changes in maternal blood histamine.
Clinically, the deported placental DAO activity in maternal blood increases a 1000 fold during normal
pregnancy (Southren et al., 1966).
The DAO activity rises exponentially in the ﬁrst 24 weeks of normal gestation and plateaus thereafter
to form a normal histamine-DAO-axis (nHDA) (Southren et al., 1966; Beaven et al., 1975; Dubois et
al., 1977) (Ahlmark, 1944; Southren et al., 1966; Gunther and Glick, 1967; Weingold and Southren,
1968; Tufvesson, 1978; Beaven et al., 1975; Dubois et al., 1977). In contrast, the spontaneous
exponential rise of DAO activity is abrogated from gestational week 8 onwards thus, leading to a
defective Histamine-DAO-Axis (dHDA) in pregnancies that present with elevated maternal blood
histamine (Southren et al., 1966; Achari, Achari and Rao, 1971; Beaven et al., 1975; Legge and Duﬀ,
1981). Ex-vivo defective Histamine-DAO-Axis also referred to Elevated Histamine Model (EHM) was
developed to mimic in vivo dHDA to study eﬀects of histamine in human placenta. The EHM was
developed by creating in vitro culture model to represent normal placentae with nHDA and
complicated placentae with dHDA. In the nHDA samples, the endogenous DAO activity is maintained
to eliminate endogenous production of histamine, while DAO activity is blocked with aminoguanidine
in the dHDA samples to allow histamine levels to elevate during the treatment period.
Aminoguanidine is a speciﬁc inhibitor of DAO enzyme activity (Tamura et al., 1989).
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Guidelines
Note:
Syncytiotrophoblast degeneration starts within 24 hours of explant culture and peaks by 48 hours.
Syncytiotrophoblast regeneration is established by120 hours of culture. Therefore culture explants
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for 5 days and apply elevated histamine treatment thereafter for a further 24 hours.
 
Explants culltured for 48 hours produced extremely poor quality RNA for high throughput
downstream analysis.
 
Micro explants incubated at the bottom of the well was associated with decreased explant viability
and poor RNA quality.
 
Protocol
Human Placental Tissue Collection and Preparation
1. Obtain ethics permission and patient consent prior to placental collection.
2. Record clinical characteristics of pregnancies for placentae to be studied as Table 1 (sample Table 1
available from
http://www.elsevier.com/__data/promis_misc/YPLAC%20Guide%20for%20authors%20Table%201.doc).
3. Collect from operating theatre term (38-39 weeks of gestation) placenta delivered by caesarean section
from normal pregnancy.
4. Inspect the placenta and record evidence for gross abnormalities such as placental infarcts, excessive
tears, necrosis, absent cotyledons, discolorations on the maternal and fetal surfaces, and anomalies in
cord insertion.
5. Cut 2 cm3 of placental samples randomly from at least 3 diﬀerent healthy looking sampling sites about
5 cm away from the umbilical cord with sterile sharp scissors.
6. Excise each sample to include an intact chorionic plate, intervillous space, basal plate and decidua.
7. Wash each placental sample in phosphate-buﬀered saline (PBS) solution (pH 7.4) containing 10%
penicillin, streptomycin and L-glutamine (Sigma) to remove excess blood and blood clots.
8. Transport each washed sample in 150 mL sterile pots containing warm PBS with 10% penicillin,
streptomycin and L-glutamine immediately to the laboratory.
9. Aseptically dissect micro explants (<50 mg wet weight) of villous tissue with sterile scalpel from each
sample.
10. Incubate the micro explant within 30 min of delivery.
Standard Culture
11. Place each fragmented micro explant on a mesh support in a 12-well culture plate containing 15mm
diameter Netwell inserts with 74µm polyester mesh bottoms attached to polystyrene inserts (Corning,
UK).
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12. Add basic media: RPMI 1640 culture medium (Invitrogen, UK) supplemented with 2 mM L-glutamine,
10% fetal bovine serum, 100 IU/ml penicillin and 100 µg/ml streptomycin.
13. Incubate micro explants in basic media at the liquid-gas interface in 8% oxygen and 5% CO2, at 37°C
for 5 days. Note: culture at the bottom of the well was associated with decreased explant viability and
poor RNA quality.
14. Replace culture media at days 2 and 4: place the media in a sterile container and expose to 8%
oxygen tension for 2 hours before the medium change is done.  Keep the time for the change of
medium to the minimum (less than 5 minutes).
Elevated Histamine Culture
15. To create the elevated histamine model, repeat media change on day 5 for elevated histamine
treatment:
1. Replace media for samples designated as dHDA samples with ﬁnal media containing 100nM
histamine in the presence of aminoguanidine (10-4 M ﬁnal concentration)
2. Replace media for samples designated as nHDA with ﬁnal basic media without aminoguanidine or
histamine.
3. Culture samples for further 24 hours
16. At the end of the 6 days culture period collect the explants and store immediately in RNAlater
(Ambion) at -80°C.
17. Store pre-culture, 0 h control samples obtained from fresh placentae in RNAlater at -80°C within 30
minutes of delivery.
